This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
申请公布号
WO2016127043(A1)
申请公布日期
2016.08.11
申请号
WO2016US16753
申请日期
2016.02.05
申请人
STC.UNM;WILSON, BRIDGET, S.;WINTER, STUART, S.;ERASMUS, MICHAEL, FRANK;HOROWITZ, MICHAEL
发明人
WILSON, BRIDGET, S.;WINTER, STUART, S.;ERASMUS, MICHAEL, FRANK;HOROWITZ, MICHAEL